CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...

Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...

At the core of this initiative is Spectris™, Cognito’s investigational, non-invasive neuroprotective device designed for at-home use. Spectris™ has shown early promise in preserving brain structure ...

In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound. Cognito was founded by MIT Professors Li-Huei Tsai and ...

- Long-term, daily proprietary gamma sensory stimulation was shown to be safe and well tolerated; treatment integrated well into subjects' daily lives. - Pivotal trials will launch this year to ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster presentations at the Alzheimer’s ...